Glycosylation of Immune Checkpoints

As we venture deeper into the realm of immune regulation, one intriguing aspect that has recently captured the attention of the scientific community is the glycosylation of immune checkpoints. In the context of immune checkpoints, the addition of sugars to these key regulatory molecules has been shown to significantly influence their localization, interaction partners, and ultimately, their immune-modulating capabilities.

The Impact of Glycosylation on Immune Checkpoints

Glycosylation adds a layer of complexity to the immune checkpoint landscape, introducing structural diversity and fine-tuning of their immunomodulatory activities.

Fig.1. The glycosylation of immune checkpoints.^1,2

• Glycosylation profoundly influences the conformation and activity of immune checkpoints. The attachment of glycans can modify the tertiary and quaternary structures of checkpoints, altering their accessibility to ligands and receptors. This dynamic interplay influences the strength and duration of immune signals, thereby shaping the immune response's outcome.
• The glycosylation patterns of immune checkpoints can be altered in various pathological conditions, including cancer and autoimmune diseases. These alterations often result in aberrant checkpoint functions, contributing to immune evasion by tumor cells or excessive immune activation against self-antigens.

Complexity of Glycosylation Profiles

One of the most intriguing aspects of glycosylation is its diversity and heterogeneity.

• Unlike DNA, which has a fixed genetic code, the sugar molecules added during glycosylation can vary significantly, resulting in a multitude of glycoforms for a given immune checkpoint. This heterogeneity creates a burst of complexity in the immune system, allowing for tailored and context-specific immune regulation.
• The different glycoforms of immune checkpoints can arise from various factors, including cell type, tissue microenvironment, and even the developmental stage of immune cells. Moreover, certain diseases may induce unique glycosylation signatures, offering diagnostic and prognostic insights and presenting novel therapeutic targets.

Glycoengineering of Immune Checkpoints

As the significance of glycosylation in immune checkpoint biology continues to be unveiled, researchers are harnessing this knowledge to design innovative therapeutic strategies. Glycoengineering, the manipulation of glycosylation patterns, emerges as a promising avenue to fine-tune the activity of immune checkpoints.

• Glycan Removal or Masking

By selectively removing specific glycans or shielding them with chemical modifications, this approach can increase the accessibility of key binding sites, enhance checkpoint-receptor interactions, and potentiate downstream signaling, thus augmenting the immune response against tumors.

• Glycan Addition

Conversely, introducing novel glycans to immune checkpoints can expand their ligand binding repertoire, broadening the range of interactions and potentially engaging new signaling pathways. This strategy can amplify the anti-tumor immune response by unlocking previously untapped immune regulation mechanisms.

• Site-Specific Glycosylation

By engineering site-specific glycosylation, researchers can tailor the immunomodulatory properties of checkpoints, enhancing anti-tumor activity while minimizing unwanted immune-related adverse events.

• Modulating Glycosyltransferase Expression

Modulating the expression or activity of these enzymes can alter the glycosylation landscape of immune checkpoints, leading to improved therapeutic outcomes.

• Combination Therapies

By strategically pairing glycoengineered immune checkpoint inhibitors with other immunotherapies, such as cancer vaccines or adoptive T-cell therapies, researchers aim to unleash the full potential of the immune system in combating cancer.

At Creative Biolabs, we remain committed to unraveling the mysteries of glycosylation and its impact on immune checkpoints, opening new pathways for researchers to develop safer and more effective therapies.

Reference

1. Zheng, Linlin, et al. "The glycosylation of immune checkpoints and their applications in oncology." Pharmaceuticals 15.12 (2022): 1451.
2. Under Open Access license CC BY 4.0, without modification.

All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic, or any in vivo human use.